Biochemical recurrence (BCR) occurs in up to 50% of men within 10 years after radical prostatectomy (RP) [1, 2]. The most commonly adopted definition of BCR is a prostate-specific antigen (PSA) level ...
A meta-analysis involving more than 6000 men suggested that adding hormone therapy (HT) to radiation after radical prostatectomy improves overall survival (OS) in those with higher pre-radiation ...
Prostate-specific antigen (PSA) recurrence after radical prostatectomy signifies increased risk of metastasis and death from prostate cancer. Traditional clinical metrics may not accurately capture ...
New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results